Table 3.
Receipt of Combination Prophylaxis Among SMARTT and WITS Infants Identified as High-Risk Based on Maternal Viral Load and Antepartum Antiretroviral Regimen
| Birth year | Total number of infants born | High-risk infants,a N (%) | Combination prophylaxisb(excluding ZDV+SD NVP) in high-risk infants, N (%) | Combination prophylaxisb(including ZDV+SD NVP) in high-risk infants, N (%) |
|---|---|---|---|---|
| 1996–2000 | 1062 | 507 (47.7) | 27 (5.3) | 36 (7.1) |
| 2001–2005 | 795 | 151 (19.0) | 18 (11.9) | 27 (17.9) |
| 2006–2010 | 1136 | 165 (14.5) | 21 (12.7) | 37 (22.4) |
| >2010 | 903 | 86 (9.5) | 25 (29.1) | 43 (50.0) |
a
High-risk defined here as maternal viral load >1000 copies/mL before labor or delivery, and/or lack of antepartum ARV therapy (or intrapartum only).
b
Combination prophylaxis defined as two or more ARV drugs used together in the first 8 weeks of life.
ARV, antiretroviral; SD NVP, single-dose nevirapine; SMARTT, Surveillance Monitoring of ART Toxicities; WITS, Women and Infant Transmission Study; ZDV, zidovudine.